aleniglipron vs ecnoglutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Obesitysmall molecule
Partial signal

NCT06703021 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: September 2028 · NCT07654361 (registry estimate)

Reported efficacy

Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Baseline and week 44); Adverse events of special interest (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature (Baseline and week 44): Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) (not_applicable)

Result source: NCT06703021

ecnoglutide

Marketed by Pfizer under a licence from Sciwind Biosciences

Phase 3 in Obesitypeptide
Reliable signal

NCT05813795 · Phase 3 · completed

SLIMMER was a randomized, double-blind, placebo-controlled Phase 3 trial at 36 centres in China. It assigned 664 adults with overweight or obesity and without diabetes to once-weekly ecnoglutide 1.2 mg, 1.8 mg or 2.4 mg or placebo. The two primary endpoints at week 40 were the percent change in body weight and the proportion of participants who lost at least 5% of their body weight. All three doses were significantly better than placebo on both endpoints (all p<0.0001), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in The Lancet Diabetes and Endocrinology.

Next expected readout: February 2027 · NCT07073417 (registry estimate)

Reported efficacy

Co-primary: percent change in body weight from baseline to week 40, and proportion of participants with at least 5% body-weight reduction at week 40: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met. (met)

Result source: NCT05813795

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointaleniglipronecnoglutide
Body weight, % change—Trial running · NCT07654361-13.2% vs 0.1%a−13.3 vs placeboecnoglutide 2.4 mg · wk 40NCT05813795
Weight loss of 5% or more—Trial running · NCT07654361—Not posted · NCT05813795
Weight loss of 10% or more—Trial running · NCT07654361—Not posted · NCT05813795
Waist circumference, change (cm)—Trial running · NCT07654361—Not posted · NCT05813795

Body weight, % change

aleniglipron
—Trial running · NCT07654361
ecnoglutide
-13.2% vs 0.1%a−13.3 vs placeboecnoglutide 2.4 mg · wk 40NCT05813795

Weight loss of 5% or more

aleniglipron
—Trial running · NCT07654361
ecnoglutide
—Not posted · NCT05813795

Weight loss of 10% or more

aleniglipron
—Trial running · NCT07654361
ecnoglutide
—Not posted · NCT05813795

Waist circumference, change (cm)

aleniglipron
—Trial running · NCT07654361
ecnoglutide
—Not posted · NCT05813795
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) NCT06703021 · Phase 2 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ecnoglutide

Weight -13.2% vs 0.1% placebo @ 40wkecnoglutide 2.4 mg
percent change · % of baseline
NCT05813795 · Phase 3 · sponsor-reported, not registry data

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT05762471 · Phase 1/2 · completed

The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.

Next expected readout: September 2028 · NCT07654374 (registry estimate)

Reported efficacy

Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM (42 days): Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo (met)

Result source: NCT05762471

ecnoglutide

Marketed by Pfizer under a licence from Sciwind Biosciences

Phase 3 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointaleniglipronecnoglutide
HbA1c, change—Trial running · NCT07654374—Not posted · NCT05680129
Body weight, change (kg)—Trial running · NCT07654374—Not posted · NCT05680129
HbA1c below 7%—Trial running · NCT07654374—Not posted · NCT05680129
Fasting plasma glucose, change—Trial running · NCT07654374—Not posted · NCT05680129
3-point MACE (% with event)—Trial running · NCT07654374—Not posted · NCT05680129

HbA1c, change

aleniglipron
—Trial running · NCT07654374
ecnoglutide
—Not posted · NCT05680129

Body weight, change (kg)

aleniglipron
—Trial running · NCT07654374
ecnoglutide
—Not posted · NCT05680129

HbA1c below 7%

aleniglipron
—Trial running · NCT07654374
ecnoglutide
—Not posted · NCT05680129

Fasting plasma glucose, change

aleniglipron
—Trial running · NCT07654374
ecnoglutide
—Not posted · NCT05680129

3-point MACE (% with event)

aleniglipron
—Trial running · NCT07654374
ecnoglutide
—Not posted · NCT05680129
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ecnoglutide: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo NCT05762471 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · ecnoglutide's landscape